We have studied the effects of oral administration of vanadate, an insulinometic agent and a potent inhibitor of phosphotyrosyl protein phosphatase (PTPase) in vitro, on blood glucose and PTPase action, in two hyperinsulinemic rodent models of noninsulin-dependent diabetes mellitus (NIDDM). Oral administration of vanadate (0.25 mg/ml in the drinking water) to ob/ob mice for 3 wk lowered blood glucose level from 236±4 to 143±2 mg/dl without effect on body weight. Administration of vanadate to db/db mice produced a similar effect. Electron microscopic examination revealed no signs of hepatotoxicity after 47 d of treatment.
Introduction
Insulin and other growth factor receptors possess intrinsic tyrosine kinase activity (1) . The binding of insulin to its receptor Receivedfor publication 15 February 1990 and in revisedform S December 1990. induces rapid autophosphorylation of the receptor which activates the tyrosine protein kinase activity towards several cellular substrates for the receptor (reviewed in reference 2). Dephosphorylation of the insulin receptor inactivates it (3, 4) . Based on several lines of evidence, it had been suggested that kinase activity is essential for some or all ofthe effects ofinsulin (5, 6) .
Vanadate is a trace element which has been shown to be a potent insulinomimetic agent in isolated adipocytes (reviewed in reference 7) . In streptozotocin (STZ)' treated diabetic rats, vanadate normalizes blood glucose (8, 9 ) and restores liver 6- phosphofructose-2-kinase glucokinase activity toward normal (10) . Vanadate has been shown to be a potent inhibitor ofphosphotyrosyl protein phosphatase (PTPase) activity in vitro at concentrations which do not inhibit phosphoserine and phosphothreonine phosphatase activity (I 1, 12). Under certain conditions, vanadate may also directly stimulate (-subunit tyrosine autophosphorylation and in vitro phosphotransferase activity of purified insulin receptors (13) , but this action has not been observed in all studies (14) . Vanadate increases glucose transport in trypsin-treated adipocytes and in cells where the insulin receptor concentration is reduced 60% by receptor downregulation (15) , suggesting a postreceptor mechanism of vanadate action.
Two well-studied rodent models of type II diabetes are ob/ ob and db/db mice. These homozygous mice are characterized by obesity, hyperglycemia, hyperinsulinemia, and a blunted response to insulin at the receptor and postreceptor levels (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . The exact etiology of the two syndromes has not been elucidated, although several glycolytic and gluconeogenic enzymes are elevated in the livers of these animals (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) ). Both models demonstrate several metabolic defects consistent with peripheral insulin insensitivity, including decreased binding to liver plasma membranes and hepatocytes (21) , increased nonsuppressible gluconeogenesis (19, 22) and failure of exogenous insulin to ameliorate the syndrome (19) . In spite of the decreased number of insulin receptors in the ob/ob and db/db mice, the kinase activity per receptor had been reported to be normal (23, 24 ; Yamada, K., et al., unpublished observation). However, in one study the insulin receptor kinase in the muscle of ob/ob mice was reported to be defective (25) . We have previously reported that vanadate normalized blood glucose in two models of insulin-deficient diabetes in rats, and that this was associated with a lowering ofelevated PTPase activity present in particulate fractions of liver (26) . In this study, we have investigated whether hepatic PTPase activity is altered in rodent models of non-insulin-dependent diabetes mellitus (NIDDM) 
Animals
Female obese-hyperglycemic mice (C57BI/6J ob/ob) and the obese diabetic mice (C57Bl/KsJ db/db) and their lean matched controls (ob/ +) and (db/+) were purchased from Jackson Laboratory (Bar Harbor, ME) and used at 6-8 wk of age. Mice were fed ad libitum a standard laboratory chow. The fed mice were anesthetized by ether and then bled through the orbital venous plexus. Venous blood and liver samples were taken between 9 and 11 a.m. As noted in the figure legends and text, some mice were treated with vanadate (0.25 mg/ml) included in the drinking water. 80 mM NaCI was also included to reduce vanadate toxicity, as previously described (8, 9) . For these experiments, control mice were treated with 80 mM NaCI alone.
Methods
Preparations of32P-labeledpeptide 1142-1153. Wheat germ agglutinin purified insulin receptor (28) The nitrocellulose membranes were then subjected to autoradiography. Electron microscopy. After cervical dislocation, the right lobe ofthe liver was rapidly excised, minced in cold 2.5% glutaraldehyde, 0.1 M phosphate buffer, pH 7.4 and fixed in fresh fixative at 4°C overnight. Tissue was rinsed in the same buffer, fixed with osmium, dehydrated in graded alcohols, and embedded in Araldite. Ultrathin sections were picked up on copper grids and stained with uranyl acetate and lead citrate. Areas adjacent to portal triads were viewed using a Phillips 301 electron microscope.
Analytic methods. Blood glucose levels were determined using ACCU-CHEC II (Boehringer Mannheim Diagnostics Division, Indianapolis, IN). Plasma immunoreactive insulin concentration was determined by radioimmunoassay using the polyethylene glycol method (31) . Serum concentrations of vanadate were determined by flameless atomic absorption spectroscopy (32). The lower limit of detection was 7 nM concentration. Protein concentrations were determined by the method of Bradford (33) using IgG immunoglobulin as a standard.
Data are presented as mean±SEM. The unpaired Student's t test (two-tailed) was used to compare two groups, and analysis of variance was used to compare more than two groups using Bonferroni correction where applicable. 
Results
Data concerning blood glucose, body weight, and plasma insulin levels in ob/ob and db/db mice and their matched controls are presented in Table I . Blood glucose and serum insulin levels, as well as the body weights, were markedly increased in the both diabetic models compared to the control mice. Effect of vanadate treatment on ob/ob mice. After 47 d of treatment with vanadate, the blood glucose level of the treated ob/ob mice was 143+2 mg/dl compared to 276±3 mg/dl in the control untreated ob/ob mice (P < 0.001, Table II and Fig. 1  A) . The vanadate treatment also lowered the blood glucose level of lean ob/+ mice from 170±4 mg/dl to 114±1 mg/dl (P < 0.001). In both the ob/ob and the ob/+ groups, there was no difference in body weight in the vanadate-treated mice as compared with their appropriate saline-treated controls (Table II) .
Circulating level of vanadate were 5.2±0.9 IAM and 2.7±0. 5 ,uM in the ob/+ mice after 3 wk of treatment. These levels are similar to vanadate levels previously reported by us and others (9, 10) . Untreated mice have no detectable (< 7 nM) serum vanadate (32) . The effect of vanadate was reversible and 20 d after withdrawal ofthe vanadate, the blood glucose returned to the initial hyperglycemic level (Fig. 1 B) . To determine the possible mechanism of this vanadate effect, we evaluated serum insulin level, insulin receptor function, and some postreceptor sites of hormone action.
Vanadate treatment increased plasma insulin levels in the ob/ob mice from 272±25 to 398±40 MU/ml (P < 0.005), but had no significant effect in the ob/+ group (57±10 to 68±15) (P> 0.05). In view ofthe fact that ob/ob mice fail to respond to even massive doses of insulin (19) and the fact that vanadate produced a similar, normoglycemic effect in db/db with a low- (Table II) . At the ultrastructural level, the livers of obese mice were heavily laden with glycogen and lipid droplets (Fig. 2) cytes from the portal triad from all groups (Fig. 2) . With both the ob/ob or lean ob/+, there was no apparent difference between vanadate-treated and control mice.
Effect of vanadate treatment on db/db mice. Treatment of db/db mice with vanadate lowered the blood glucose level from 228±6 to 141±1 mg/dl (P < 0.001). This effect was maximal after 55 d of treatment, with half the effect observed after 23 d (Fig. 3) . This was associated with a 40% decrease in insulin level (Table III) . The vanadate treatment also lowered the blood glucose level ofthe db/+ mice from 126±2 to 81 ± 1 mg/dl after 55 d. There was no difference in body weight gain during treatment with vanadate or with saline for either the db/db or the db/+ groups (Table III) . The effect of vanadate was reversible, and 25 d after withdrawal of the vanadate the blood glucose returned to the initial hyperglycemic level (Fig. 3) . Effect ofdiabetes and vanadate on PTPase activity. PTPase activity present in cytosolic extracts of liver from the 8-wk-old ob/ob mice was 55% that of the ob/+ (0.18+0.02 U/mg and 0.33±0.03 U/mg, P < 0.01) when assessed in vitro using the phosphorylated 1142-1153 peptide as substrate (Fig. 4 A) Time (days)
PTPase activity associated with the particulate fractions was similarly decreased in the ob/ob mice versus the ob/+ controls v (1.4±0.2 U/mg and 2.1±0.3 U/mg, P < 0.02) (Fig. 4 B) . The ti glycoprotein fraction of the membrane had five-to eightfold fi higher specific activity than the particulate fraction, however, 1 l specific activities of the PTPase in the WGA-purified particuli late fractions were not different between ob/ob and ob/+ mice In (16.1±1.3 U/mg vs. 16.8±1 U/mg, Fig. 3 B) . Fi In the 8-wk-old db/db mice, the cytosolic PTPase activity a was also decreased by 50% (0.25±0.03 U/mg vs. 0.47±07 U/mg, P < 0.02) (Fig. 5 A) . No significant difference was found p in the PTPase activity associated with the particulate fraction i] (Fig. 5 B) , and thus activity in the glycoprotein fractiona enriched fraction was not determined. Figure 3 . Effect of oral administration of vanadate on blood glucose level in db/db mice. Db/db mice (solid line) and their match controls db/+ (dashed line) were treated with vanadate as described in Fig. 1 . 60 d after treating the mice, the vanadate had been changed into the control solution. Each point is the mean of five or six mice. SEM was 2-3 mg/dl.
Effect ofvanadate treatment on tyrosyl phosphorylation in ivo of95 and 185 kD. To determine whether the administra-;ion of vanadate produced its insulinomimetic metabolic efects by increasing activation of the insulin receptor, we anayzed the phosphotyrosyl proteins which occur in intact mouse iver using an anti-phosphotyrosine antibody immunoblotting ;nethod. After insulin infusion into the portal vein of intact, ive mice, phosphotyrosyl proteins were isolated and analyzed is described in Experimental Procedures.
Without acute insulin infusion, a major, constitutively ?hosphotyrosine-containing protein ofMr 120 kD was present n all animals (Fig. 7) . The identity of this band is unknown, although it has been previously observed (34) , and its phospho-,yrosine content was not influenced by vanadate or insulin .reatment. There was also a low level of 3-subunit phosphotyrosine attributable to receptor activation by endogenous, circuating insulin (Fig. 7 , at M, 95 kD compare lane 5 with I and ane 7 with 3), however, vanadate treatment did not increase -his basal level of insulin receptor autophosphorylation. This bservation was replicated in three experiments in both ob/+ .nd ob/ob (-12.1 ± 13.4%; mean percent difference of control vs. vanadate treated±SD, n = 6). Moreover, no new phospho--yrosyl proteins were detected in the vanadate-treated mice ompared with control mice. After intraportal insulin infusion a 95-kD band, consistent ovith the insulin receptor 1-subunit, became prominently phos-?horylated (Fig. 7, lanes 2, 4, 6, 8 + ins) . The extent ofreceptor utophosphorylation is similar in all animals, although there vas a modest decrease (-38+10%; mean±SD, n = 3) in the )b/ob diabetic mice compared with ob/+ controls. Vanadate reatment did not significantly alter receptor autophosphorylation in either the ob/+ mice (17% mean increase, n = 2) or in the ob/ob diabetic animals (26% decrease, n = 1).
In addition to the 95-kD receptor band, insulin infusion ,timulated the appearance ofa distinct phosphotyrosyl protein migrating between 170 and 185 kD. This has been previously Ldentified as ppl85, a putative, endogenous substrate of the insulin receptor kinase (34) . In the ob/+ mouse liver, ppl85 Lppeared as a closely spaced protein doublet, whereas in the zb/ob mice the upper band ofpp 185 was of much lower intensity as compared to ob/+ controls (Fig. 7 Liver fraction derived from ob/ob and ob/+ mice were fractionated using isotonic sucrose differential centrifugation. The particulate fraction was then further fractionated on WGA columns. The 1142-1 153 peptide was phosphorylated at 4VC in the presence of 100 nM insulin using WGA-purified insulin receptor as described in the methods. The 32P-labeled peptide was separated from the 32P-ATP by chromatography on AG 1-X2 acetate column and by SEP-PAK cartridge and 1yophilized. Aliquots from each fraction were assayed for PTPase activity towards the phosphorylated peptides (0.14 ,M)
in the presence of 2 mM EDTA and 1 mM DTT for 5 min at 30'C.
The reaction was stopped by precipitation with 10% TCA, and 32Pi release was measured by organic extraction of Pi (27) . tyrosine phosphorylation in either ob/+ or ob/ob mice (Fig. 7 , compare lane 5 with 1, and lane 7 with 3; 7.3±12.5%; mean difference of control vs. vanadate treated±SD, n = 6). The effect of vanadate treatment on the extent of stimulated pp 185 tyrosine phosphorylation after acute insulin infusion was variable with a twofold augmentation in ob/+ mice in the experiment shown in Fig. 7 (lane 6 vs. lane 2), but no such augmentation was not evident in ob/ob mice (compare lane 8 with lane 4), nor was it as evident in a replicate experiment with ob/+ controls.
Discussion
Tyrosine phosphorylation is an important regulatory process (1, 2, (35) (36) (37) . The level of phosphotyrosine in the cell is a balance between the actions of protein tyrosine kinases and protein tyrosine phosphatases. In nontransformed tissues, the major tyrosyl kinases are the receptors for certain peptide hor- mones and growth factors, such as insulin, IGF-I, epidermal growth factor and platelet-derived growth factor. PTPase activity has been detected in a variety of tissues and cell lines. These enzymes have molecular weights between 23 kD (in rat brain) and 200 kD (CD 45 in lymphocytes) and are distinct from phosphoserine phosphatases based on their primary sequence, substrate specificity, activity in the presence of EDTA and sodium fluoride, selective inhibition by micromolar concentration of zinc and vanadate (reviewed in references 38, 39) . The exact number ofenzymes in the family, their physiologic roles, and their regulation are uncertain. We have studied the alterations in hepatic PTPase and tyrosine phosphorylation as a possible explanation for blunted response to insulin in two rodent models of obesity-associated diabetes, the ob/ob and db/db mice (16, 40) . The decrease in tivity from the ob/ob mice livers was assayed as described in Fig. 3 . The results represent mean±SEM of five mice in each group assayed in duplicate. *P < 0.02. insulin action in these models is associated with decreased receptor number (16, 21, 25) , but the activity of the receptor tyrosine kinase, when corrected per insulin binding, appears to be normal (23, 24 ; Yamada, K., et al., personal communication). Thus, the major defects in these models seem to be a decrease in the number of insulin receptors and alterations at the postreceptor level. In both models there were significant decreases in the cytosolic PTPase activity, whereas the particulate PTPase activity decreased significantly only in ob/ob mice. Although a synthetic substrate was used in these studies for improved quantitation, the tissue preparations were also active in dephosphorylation of the autophosphorylated insulin receptor under the same assay conditions (26, Meyerovitch, J., J. M. Backer, M. F. White, and C. R. Kahn, submitted for publication), suggesting that the PTPases being assessed are those which are potentially involved in the insulin receptor dephosphorylation.
The exact relationship between the cytosolic, particulate, and glycoprotein-enriched PTPase activities is uncertain; however, some differences have been noted between the enzyme activities in these two fractions. Previous work (41) has suggested that a membrane-bound PTPase in the kidney can be distinguished from its cytosolic counterpart based on differential elution from DEAE-Sepharose, thermal lability, and sensitivity to dodecyl sulfate. On the other hand, Tonks et al. (42) reported that little difference could be detected between the cytosolic and particulate forms of the enzymes purified from human placenta. In previous studies, we reported that the two enzymes are different both in response to acute stimulation with insulin (Meyerovitch et (9) . Although vanadate has been shown to reduce appetite in normal rats through an effect in the central nervous system (49), the hypoglycemic effect in the NIDDM rodent models occurs without an effect on body weight, suggesting that the mechanism of action of vanadate is not mediated through decreased food intake. The exact site of action of vanadate remains uncertain (reviewed in reference 7). Some groups have found that vanadate directly stimulates 3-subunit tyrosine autophosphorylation and in vitro phosphotransferase activity of purified insulin receptors (13) , but this has not been observed in all studies (14). One previous study suggests that the effect of vanadate is not mediated through changes in the phosphorylation of the insulin receptor (50) . In this study we have found that vanadate produced a variable enhancement of insulin-stimulated tyrosine phosphorylation of ppl 85 in the ob/+ mice but had no effect in ob/ob mice. Our study differs from the former study in that the administration of vanadate was chronic rather than acute. In addition, we have used a technique which enables a rapid isolation of phosphoproteins and thereby increases the sensitivity of the assay. The lack of effect of vanadate administration on the level of tyrosine phosphorylation of the p3-subunit of the insulin receptor and its putative substrate in ob/ob mice suggests that its primary action may be at a step distal to these tyrosine phosphorylations. However, we cannot rule out changes in tyrosine phosphorylation of substrates which could be detected only under other conditions (5 1).
Vanadate can affect directly the activity of several enzymes in vitro (7), and vanadate administration has been shown to restore the level of fructose 2,6-biphosphate activity in the STZ diabetic rats (10) and normalize the glucose uptake and glycogen synthetase in diabetic muscle (52) . Normalization of the activity of these enzymes which are increased in both mice models of NIDDM (17) (18) (19) (20) is a possible mechanism of action of vanadate.
This study demonstrates that vanadate is an effective oral hypoglycemic agent and produces a normoglycemic state in two rodent models ofNIDDM. This effect appears to occur as a result ofaction at a step distal to the tyrosine phosphorylations of the insulin receptor and the ppl 85. No hepatotoxicity was detected in the present study at the ultrastructure level after 7 wk of vanadate treatment. Likewise, no changes in liver or kidney function have been reported by us and others in STZ diabetic rats (9) . Although more studies are necessary to evaluate the long-term toxicity, and the appropriate dose of vanadate, these data suggest that vanadate administration may offer a new therapeutic approach to diabetes and insulin resistance states either alone or in combination with conventional therapy.
